أحمد الشهري | طبيب أورام 🇸🇦(@DrAhmedAlShehri) 's Twitter Profile Photo

وبدأ المؤتمر الأكبر عالمياً لطب الأورام .. قبل نحو ساعة ..
كان يُعقد سنوياً في مدينة شيكاغو الساحرة بولاية إلينوي .. نحو هذا الوقت من العام ..
السنة الماضية وهذه السنة يُعقد على المنصة الافتراضية ..
يوجد العديد مما يتوقع أن يكون له أثر على تغيير نمط علاج عدة سرطانات ..

وبدأ المؤتمر الأكبر عالمياً لطب الأورام .. قبل نحو ساعة ..
كان يُعقد سنوياً في مدينة شيكاغو الساحرة بولاية إلينوي .. نحو هذا الوقت من العام ..
السنة الماضية وهذه السنة يُعقد على المنصة الافتراضية ..
يوجد العديد مما يتوقع أن يكون له أثر على تغيير نمط علاج عدة سرطانات ..
#ASCO2021
account_circle
Daniel Castellano(@cdanicas) 's Twitter Profile Photo

👏👏PLENARY SESSION
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)

👏👏PLENARY SESSION #ASCO2021 #ASCO21 
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)
account_circle
Ignacio Garrido-Laguna(@GarridoLagunaMD) 's Twitter Profile Photo

The PRINCE trial team to be commended for well conducted trial evaluating sotigalimab (aCD40) in . Soti shows on target effect but adds nothing (and maybe even antagonistic)= No-go

The PRINCE trial team to be commended for well conducted trial evaluating sotigalimab (aCD40) in #pancreaticcancer. Soti shows on target effect but adds nothing (and maybe even antagonistic)= No-go #ASCO2021
account_circle
Dr Sarah Nadeem(@SarahNadeemMD) 's Twitter Profile Photo

Today is . I'm fortunate 2 still b here 7y post affects evrything,life changed permanently,if anything it taught me 2 take each day as it comes,appreciate blessings, thru challenges,(physical&emotional) SurvivorsDay

Today is #survivorday. I'm fortunate 2 still b here 7y post #breastcancer #Cancer affects evrything,life changed permanently,if anything it taught me 2 take each day as it comes,appreciate blessings, #keepmoving thru challenges,(physical&emotional) #ASCO2021 #CancerSurvivorsDay
account_circle
د.أطلال أبوسند(@atlal_abusanad) 's Twitter Profile Photo

Having the opportunity to present the 1st study on among from ASCO
Check out the video👉 meetings.asco.org/abstracts-pres…
A subset analysis of the large onlinelibrary.wiley.com/doi/abs/10.100…

Having the opportunity to present the 1st study on #Burnout among #FemaleOncologists from #MENA @ASCO  #ASCO21 #ASCO2021 #Genderequity #WomenInMedicine
Check out the video👉 meetings.asco.org/abstracts-pres…
A subset analysis of the large #BOMENA_study onlinelibrary.wiley.com/doi/abs/10.100…
account_circle
Rana McKay(@DrRanaMcKay) 's Twitter Profile Photo

Landmark data from KN564 presented by ⁦Toni Choueiri, MD⁩ - positive DFS, strong OS signal. We finally enter into a new adjuvant era in RCC. ⁦ASCO

Landmark data from KN564 presented by ⁦@DrChoueiri⁩ - positive DFS, strong OS signal. We finally enter into a new adjuvant era in RCC. ⁦@ASCO⁩ #asco2021
account_circle
Benjamin Besse(@BenjaminBesseMD) 's Twitter Profile Photo

DZD9008, a new drug in the EGFR Ex20 space?
Toxicity on all pts: 4.9% Grade3+ diarrhea is artificially low because mixes any dose levels.
Efficacy (only pts with high dose levels): ORR 39.6%.
Phase II data needed (ORR w pozio dropped from ~40 to 15% in larger dataset)!

DZD9008, a new drug in the EGFR Ex20 space?#ASCO2021 
Toxicity on all pts: 4.9% Grade3+ diarrhea is artificially low because mixes any dose levels.
Efficacy (only pts with high dose levels): ORR 39.6%.
Phase II data needed (ORR w pozio dropped from ~40 to 15% in larger dataset)!
account_circle
Tom Powles(@tompowles1) 's Twitter Profile Photo

Asco session: This trial would be perhaps the most ambitious way of curing a high proportion of patients UC, while avoiding cystectomy where possible, and only giving adjuvant therapy to those that need it. Can we do this study? I hope in parts at least. joaquim bellmunt

Asco session: This trial would be perhaps the most ambitious way of curing a high proportion of patients UC, while avoiding cystectomy where possible, and only giving adjuvant therapy to those that need it. Can we do this study? I hope in parts at least.  #ASCO2021 @OncoBellmunt
account_circle
Sarah Temkin(@temkins) 's Twitter Profile Photo

For we examined gender differences in practice characteristics and support for gynecologic oncologist and whether they might explain the in our subspecialty. We are a majority women specialty and the 'canary in the coalmine' of inclusion 1/

For #ASCO2021 we examined gender differences in practice characteristics and support for gynecologic oncologist and whether they might explain the #genderwagegap in our subspecialty. We are a majority women specialty and the 'canary in the coalmine' of inclusion 1/
account_circle
TARGED(@WebTarged) 's Twitter Profile Photo

09 Haziran 2021, Çarşamba Saat: 19.00 - 20.00 arasında gerçekleşecek olan ''ASCO 2021'den BildiriYORUM'' canlı yayınımıza bekleriz. Canlı yayına ulaşmak için; webtarged.org
2021

09 Haziran 2021, Çarşamba Saat: 19.00 - 20.00 arasında gerçekleşecek olan ''ASCO 2021'den BildiriYORUM'' canlı yayınımıza bekleriz. Canlı yayına ulaşmak için; webtarged.org
#ASCO #ASCO2021 #WebTARGED #targed #OnkolojininMultidisiplinerPlatformu
account_circle